Filing Details
- Accession Number:
- 0001179110-18-012203
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2018-10-16 16:17:20
- Reporting Period:
- 2018-10-05
- Accepted Time:
- 2018-10-16 16:17:20
- Original Submission Date:
- 2018-10-09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1235007 | Endocyte Inc | ECYT | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1509415 | P Christopher Leamon | 3000 Kent Ave, Suite A1-100 West Lafayette IN 47906 | Vice President Of Research | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2018-10-05 | 9,028 | $15.56 | 122,219 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Represents the sale of 9,028 shares in multiple transactions, ranging in price from $15.1300 to $15.9200, resulting in a weighted-average sale price per share of $15.5557. The 9,028 shares were sold to cover taxes, commissions and fees associated with the October 4, 2018 settlement of 20,000 restricted stock units in the form of Company common stock on a one-for-one basis. The shares were sold pursuant to a written plan as specified in Rule 10b5-1(c) of the Securities Exchange Act of 1934.
- Includes 866 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on June 15, 2018 that were inadvertently omitted from the amount of securities beneficially owned by the reporting person as reported on subsequent Form 4s.
Billionaire Hedge Funds
